Protagonist Therapeutics (PTGX) Operating Margin (2017 - 2025)
Historic Operating Margin for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 985.17%.
- Protagonist Therapeutics' Operating Margin fell 984700.0% to 985.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.34%, marking a year-over-year decrease of 381800.0%. This contributed to the annual value of 58.2% for FY2024, which is 2142900.0% up from last year.
- Protagonist Therapeutics' Operating Margin amounted to 985.17% in Q3 2025, which was down 984700.0% from 758.04% recorded in Q2 2025.
- In the past 5 years, Protagonist Therapeutics' Operating Margin registered a high of 80.92% during Q1 2024, and its lowest value of 4604.78% during Q2 2022.
- In the last 5 years, Protagonist Therapeutics' Operating Margin had a median value of 388.12% in 2021 and averaged 710.36%.
- As far as peak fluctuations go, Protagonist Therapeutics' Operating Margin crashed by -100797100bps in 2021, and later soared by 3971100bps in 2022.
- Protagonist Therapeutics' Operating Margin (Quarter) stood at 429.57% in 2021, then soared by 92bps to 32.46% in 2022, then skyrocketed by 242bps to 46.1% in 2023, then skyrocketed by 67bps to 76.84% in 2024, then crashed by -1382bps to 985.17% in 2025.
- Its Operating Margin stands at 985.17% for Q3 2025, versus 758.04% for Q2 2025 and 68.18% for Q1 2025.